🇺🇸 FDA
Patent

US 10925971

Methods of treating PRLR positive breast cancer

granted A61KA61K2039/505A61K31/198

Quick answer

US patent 10925971 (Methods of treating PRLR positive breast cancer) held by REGENERON PHARMACEUTICALS, INC. expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
34
CPC classes
A61K, A61K2039/505, A61K31/198, A61K31/27, A61K31/565